All In Biotech

Drug Trial Radar · NCT00054717

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

Randomized, Open-label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-dose Ritonavir (TPV/RTV) Verses Genotypically-defined Protease Inhibitor/Ritonavir (PI/RTV) in Multiple Antiretroviral Drug-experienced Patients.

Last checked: Nov 20, 2026Latest source record: Jul 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

630

Actual

Start

Jan 2003

Primary completion

Sep 2008

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Feb 10, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.

Conditions

  • HIV Infections

Interventions

  • TipranavirDrug

  • Ritonavir(r)Drug

  • Comparator Protease Inhibitor (CPI)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Response at Week 48Time frame: At week 48
  2. Time to Treatment Failure Through 48 Weeks of TreatmentTime frame: Week 48

Locations

117 sites in 4 countries. Site status is shown where the registry gives one.

  • 1182.12.62 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 1182.12.108 El Rio SIA

    Tucson, Arizona

  • 1182.12.9 Boehringer Ingelheim Investigational Site

    Berkeley, California

  • 1182.12.23 Boehringer Ingelheim Investigational Site

    Beverly Hills, California

  • 1182.12.12 Boehringer Ingelheim Investigational Site

    Fountain Valley, California

  • 1182.12.76 Boehringer Ingelheim Investigational Site

    Long Beach, California

  • 1182.12.1 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1182.12.59 David Geffen School of Medicine at UCLA

    Los Angeles, California

  • 1182.12.82 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1182.12.97 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1182.12.69 UC Davis Medical Center

    Sacramento, California

  • 1182.12.89 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1182.12.99 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 1182.12.25 Boehringer Ingelheim Investigational Site

    San Francisco, California

  • 1182.12.5 Boehringer Ingelheim Investigational Site

    San Francisco, California

  • 1182.12.53 Boehringer Ingelheim Investigational Site

    San Francisco, California

  • 1182.12.98 University of Colorado Health Sciences Center

    Denver, Colorado

  • 1182.12.7 Boehringer Ingelheim Investigational Site

    Norwalk, Connecticut

  • 1182.12.103 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 1182.12.52 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 1182.12.70

    Washington D.C., District of Columbia

  • 1182.12.79 Boehringer Ingelheim Investigational Site

    Fort Lauderdale, Florida

  • 1182.12.77 Boehringer Ingelheim Investigational Site

    Fort Myers, Florida

  • 1182.12.45 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1182.12.75 CARES Resource

    Miami, Florida

  • 1182.12.85 Boehringer Ingelheim Investigational Site

    Miami, Florida

  • 1182.12.93 Boehringer Ingelheim Investigational Site

    Miami Beach, Florida

  • 1182.12.17 Boehringer Ingelheim Investigational Site

    Orlando, Florida

  • 1182.12.90 Boehringer Ingelheim Investigational Site

    Sarasota, Florida

  • 1182.12.63 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1182.12.78 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 1182.12.94 Infectious Disease Research Institute

    Tampa, Florida

  • 1182.12.67 Boehringer Ingelheim Investigational Site

    Vero Beach, Florida

  • 1182.12.123 Infectious Disease Clinics of Emory

    Atlanta, Georgia

  • 1182.12.88 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 1182.12.72 Boehringer Ingelheim Investigational Site

    Decatur, Georgia

  • 1182.12.47 Boehringer Ingelheim Investigational Site

    Macon, Georgia

  • 1182.12.8 Family Practice Medical Center

    Boise, Idaho

  • 1182.12.105 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 1182.12.3 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.